(MedPage Today) — The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday.
The once-daily 25 mg pill is approved to lower…
Gleneagles Hospitals organises conference on advances in head and neck cancer care
Experts discussed emerging therapies, reconstructive surgery, and multidisciplinary treatment approaches in head and neck cancer care Source: www.thehindu.com Medical Disclaimer:...





